Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial.

dc.contributor.author

Taylor, Hugh

dc.contributor.author

Li, Howard J

dc.contributor.author

Carson, Sandra

dc.contributor.author

Flores, Valerie

dc.contributor.author

Pal, Lubna

dc.contributor.author

Robbins, Jared

dc.contributor.author

Santoro, Nanette F

dc.contributor.author

Segars, James H

dc.contributor.author

Seifer, David

dc.contributor.author

Huang, Hao

dc.contributor.author

Young, Steven

dc.contributor.author

Zhang, Heping

dc.date.accessioned

2023-10-01T15:13:06Z

dc.date.available

2023-10-01T15:13:06Z

dc.date.issued

2022-06

dc.date.updated

2023-10-01T15:13:06Z

dc.description.abstract

Introduction

Infertility is a common complication of endometriosis. While in vitro fertilisation-embryo transfer (IVF) successfully treats endometriosis-associated infertility, there is some evidence that pregnancy rates may be diminished in women seeing fertility treatment for endometriosis-associated infertility compared with other etiologies of infertility. The use of gonadotropin releasing hormone (GnRH) agonist prior to IVF has been suggested to improve success, however studies have been small and rarely reported live birth rates. Recent approval of an oral GnRH antagonist for endometriosis provides a novel option for women with endometriosis who are undergoing IVF. There have been no studies on the efficacy of GnRH antagonists for the treatment of endometriosis-related infertility.

Methods and analysis

This study is a multicentre, prospective, randomised, double-blind, placebo-controlled trial to study the efficacy of GnRH antagonist pretreatment for women with endometriosis who are undergoing IVF. A total of 814 patients with endometriosis undergoing fertility treatment will be enrolled and randomised 1:1 into two groups: elagolix 200 mg two times per day or placebo for 8 weeks, prior to undergoing IVF. All participants will then undergo IVF treatment per local protocols. The primary outcome is live birth. Secondary outcomes include oocyte number, fertilisation rate, embryo morphology and implantation rates, as well as rates of known endometriosis-related obstetrical outcomes (pregnancy-induced hypertension, antepartum haemorrhage, caesarean delivery and preterm birth).

Ethics and dissemination

The PREGnant trial was approved by the Institutional Review Board at Johns Hopkins University. Results will be published in a peer-reviewed journal.

Trial registration number

NCT04173169.
dc.identifier

bmjopen-2021-052043

dc.identifier.issn

2044-6055

dc.identifier.issn

2044-6055

dc.identifier.uri

https://hdl.handle.net/10161/29058

dc.language

eng

dc.publisher

BMJ

dc.relation.ispartof

BMJ open

dc.relation.isversionof

10.1136/bmjopen-2021-052043

dc.subject

Humans

dc.subject

Infertility

dc.subject

Endometriosis

dc.subject

Premature Birth

dc.subject

Fertilization in Vitro

dc.subject

Ovulation Induction

dc.subject

Pregnancy Rate

dc.subject

Prospective Studies

dc.subject

Pregnancy

dc.subject

Infant, Newborn

dc.subject

Female

dc.subject

Gonadotropin-Releasing Hormone

dc.subject

Multicenter Studies as Topic

dc.subject

Randomized Controlled Trials as Topic

dc.title

Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial.

dc.type

Journal article

duke.contributor.orcid

Young, Steven|0000-0002-5205-4495

pubs.begin-page

e052043

pubs.issue

6

pubs.organisational-group

Duke

pubs.organisational-group

School of Medicine

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Obstetrics and Gynecology

pubs.organisational-group

Obstetrics and Gynecology, Reproductive Endocrinology & Fertility

pubs.publication-status

Published

pubs.volume

12

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT) study protocol for a prospective, double-bli.pdf
Size:
268.46 KB
Format:
Adobe Portable Document Format
Description:
Published version